PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1739633-4	1992	NSE monitored the effect of cisplatin-based chemotherapy in patients with metastases.	Cisplatin	28-37	enolase 2	Homo sapiens	0-3	
1755298-2	1991	The initial response to induction chemotherapy, especially to VP16/cisplatin was evaluated by determining t 1/2 for urinary vanillylmandelic acid (VMA), homovanillic acid and serum neuron specific enolase (NSE).	Cisplatin	67-76	enolase 2	Homo sapiens	181-204	
1755298-2	1991	The initial response to induction chemotherapy, especially to VP16/cisplatin was evaluated by determining t 1/2 for urinary vanillylmandelic acid (VMA), homovanillic acid and serum neuron specific enolase (NSE).	Cisplatin	67-76	enolase 2	Homo sapiens	206-209	
33413292-7	2021	ADT and subsequent chemotherapy with etoposide and cisplatin (EP) were performed for prostate cancer, which resulted in decreased PSA and NSE and reduction of all metastases.	Cisplatin	51-60	enolase 2	Homo sapiens	138-141	
34216375-5	2021	The tumor shrank with gemcitabine/cisplatin therapy; however, neuron-specific enolase (NSE) and CYFRA levels were increased and the tumor grew.	Cisplatin	34-43	enolase 2	Homo sapiens	62-85	
34216375-5	2021	The tumor shrank with gemcitabine/cisplatin therapy; however, neuron-specific enolase (NSE) and CYFRA levels were increased and the tumor grew.	Cisplatin	34-43	enolase 2	Homo sapiens	87-90	
34216375-6	2021	Next, hepatic arterial infusion chemotherapy using 5-fluorouracil and cisplatin decreased NSE and CYFRA levels and suppressed tumor growth.	Cisplatin	70-79	enolase 2	Homo sapiens	90-93	
26633178-12	2015	Six courses of the gemcitabine/cisplatin chemotherapy achieved partial response of metastatic lesions, with serum neuron-specific enolase levels decreasing from 118 ng/mL to 2.6 ng/mL.	Cisplatin	31-40	enolase 2	Homo sapiens	114-137